While the company claimed a victory, analysts said data from a Phase 1/2 study fell short of expectations. Entrada shares subsequently tumbled more than 50%.
An article from
Dive Brief
While the company claimed a victory, analysts said data from a Phase 1/2 study fell short of expectations.
Published May 7, 2026
By
A next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make…
Satellos shares adult TRAILHEAD data on Duchenne pill SAT-3247 ahead of a potentially pivotal BASECAMP readout in children by…
A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as…
U.S. stock futures down on tech profit-taking and weak guidance, ADC Therapeutics shares plunge 50.67%, other stocks also slide.
While the market's enthusiasm for one of Zealand's experimental drugs has cooled, investors are shifting focus to amylin-based…
Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring…
